Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sodium phenylbutyrate for glucose homeostasis in type 2 diabetes
NL-OMON60761Phase 4Recruiting
- Sponsor
- Maastricht University
- Start
- Apr 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, single-arm trial of sodium phenylbutyrate in type 2 diabetes mellitus (T2DM), sponsored by Maastricht University. Primary endpoint: Fasting plasma glucose. Started Apr 2025; status: recruiting.
02
Drugs
sodium phenylbutyrate
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NL-OMON60761.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON60761.